MET and lung carcinoma: Turke et al. identified subpopulations of cells with MET amplification within EGFR-mutant lung cancers prior to drug treatment [52], which contributes to gefitinib resistance when activated by HGF through a PI3K/AKT/GAB1 signaling pathway.